Chile Menopause Drugs Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 OVERVIEW OF CHILE MENOPAUSE DRUGS MARKET 14
1.4 CURRENCY AND PRICING 15
1.5 LIMITATIONS 16
1.6 MARKETS COVERED 16
2 CHILE MENOPAUSE DRUGS MARKET: SEGMENTATION 19
2.1 MARKETS COVERED 19
2.2 COUNTRY SCOPE 20
2.3 YEARS CONSIDERED FOR THE STUDY 20
2.4 DBMR TRIPOD DATA VALIDATION MODEL 21
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 24
2.6 MULTIVARIATE MODELLING 25
2.7 CAUSE SEGMENT LIFELINE CURVE 25
2.8 DBMR MARKET POSITION GRID 26
2.9 VENDOR SHARE ANALYSIS 27
2.10 MARKET END USER COVERAGE GRID 28
2.11 SECONDARY SOURCES 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 33
4.1 EPIDEMIOLOGY 34
4.2 PESTEL'S MODEL 35
4.3 PORTER'S FIVE FORCES MODEL 36
5 PIPELINE ANALYSIS FOR CHILE MENOPAUSE DRUGS MARKET 37
6 CHILE MENOPAUSE DRUGS MARKET, COUNTRY SUMMARY 38
6.1 OVERVIEW 38
7 CHILE MENOPAUSE DRUG TREATMENT MARKET: REGULATORY SCENARIO 39

8 MARKET OVERVIEW 42
8.1 DRIVERS 44
8.1.1 LOW AGE OF MENOPAUSE DISORDER OCCURRENCE AS COMPARED TO OTHER REGIONS 44
8.1.2 RISE IN AGEING POPULATION AMONG WOMEN IN CHILE 44
8.1.3 RISE IN RESEARCH AND DEVELOPMENT 45
8.1.4 RISE IN PHYSICAL INACTIVITY AND SEDENTARY LIFESTYLE 45
8.1.5 REIMBURSEMENT FOR MENOPAUSE TREATMENT 46
8.2 RESTRAINTS 46
8.2.1 RISE IN COST OF THE MENOPAUSE DRUGS 46
8.2.2 PATENT EXPIRY 47
8.2.3 COMPLEXITY IN MENOPAUSE 47
8.2.4 LACK OF AWARENESS ABOUT MENOPAUSE 48
8.3 OPPORTUNITIES 48
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 48
8.3.2 RISE IN HEALTHCARE EXPENDITURE 49
1.3.2 PRESENCE OF A STRONG PRODUCT PIPELINE 49
8.4 CHALLENGES 50
8.4.1 ADVERSE EFFECTS OF MEDICATION 50
8.4.2 AVAILABILITY OF ALTERNATIVES 50
9 IMPACT OF COVID-19 ON CHILE MENOPAUSE DRUG TREATMENT MARKET 51
9.1 IMPACT ON PRICE 51
9.2 IMPACT ON SUPPLY CHAIN 52
9.3 IMPACT ON DEMAND 53
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS 53
9.5 CONCLUSION 53
10 CHILE MENOPAUSE DRUGS MARKET, BY STAGES 54
10.1 OVERVIEW 55
10.2 POSTMENOPAUSE 57
10.3 PERIMENOPAUSE 58
10.4 MENOPAUSE 58

11 CHILE MENOPAUSE DRUGS MARKET, BY TYPE 59
11.1 OVERVIEW 60
11.2 NON-HORMONAL THERAPY 62
11.2.1 MEDICATION 63
11.2.1.1 ANTI-DEPRESSANTS 63
11.2.1.2 PAROXETINE 63
11.2.1.3 GABAPENTIN 63
11.2.1.4 CLONIDINE 64
11.2.1.5 OSPEMIFENE 64
11.2.1.6 OTHERS 64
11.2.2 SUPPLEMENTS 64
11.2.2.1 HERBAL SUPPLEMENTS 64
11.2.2.1.1 GINSENG 65
11.2.2.1.2 ASHWAGANDHA 65
11.2.2.1.3 OTHERS 65
11.2.2.2 VITAMIN D 65
11.2.2.3 OTHERS 65
11.3 HORMONAL THERAPY 65
11.3.1 ESTROGEN 66
11.3.1.1 17 B- ESTRADIOL 66
11.3.1.2 CONJUGATED ESTROGEN 66
11.3.1.3 ESTRADIOL HEMIHYDRATE 66
11.3.1.4 ESTERIFIED ESTROGEN 66
11.3.1.5 ESTERIFIED ACETATE 67
11.3.1.6 ESTROPIPATE 67
11.3.1.7 OTHERS 67
11.3.2 COMBINES ESTROGEN & PROGESTOGEN DRUGS 67
11.3.2.1 17 B- ESTRADIOL (E) + NORETHINODRONE ACETATE (P) 67
11.3.2.2 CONJUGATED ESTROGENS (E) + MEDROXYPROGESTERONE ACETATE (P) 67
11.3.2.3 ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) 67
11.3.2.4 OTHERS 68
11.3.3 MEDROXYPROGESTERONE ACETATE 68
12 CHILE MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS 69
12.1 OVERVIEW 70
12.2 VASOMOTOR SYMPTOMS 73
12.2.1 HORMONAL THERAPY 73
12.2.2 NON-HORMONAL THERAPY 73

12.3 ATROPHIC VAGINITIS 74
12.3.1 HORMONAL THERAPY 75
12.3.2 NON-HORMONAL THERAPY 75
12.4 DYSPAREUNIA 75
12.4.1 HORMONAL THERAPY 76
12.4.2 NON-HORMONAL THERAPY 76
12.5 OSTEOPOROSIS 76
12.5.1 NON-HORMONAL THERAPY 77
12.5.2 HORMONAL THERAPY 77
12.6 DEPRESSION 77
12.6.1 NON-HORMONAL THERAPY 78
12.6.2 HORMONAL THERAPY 78
12.7 JOINT PAIN 78
12.7.1 NON-HORMONAL THERAPY 78
12.7.2 HORMONAL THERAPY 78
12.8 WEIGHT GAIN 79
12.8.1 HORMONAL THERAPY 79
12.8.2 NON- HORMONAL THERAPY 79
12.9 OTHERS 79
13 CHILE MENOPAUSE DRUGS MARKET, BY DOSAGE FORM 81
13.1 OVERVIEW 82
13.2 TABLET 85
13.3 CREAM 85
13.4 PATCH/FILM 85
13.5 RINGS 86
13.6 GEL 86
13.7 INJECTION SHOT 87
13.8 SPRAY 87
13.9 OTHERS 87
14 CHILE MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION 89
14.1 OVERVIEW 90
14.2 ORAL 93
14.3 PARENTERAL 93
14.3.1 INTRAVENOUS 94
14.3.2 SUBCUTANEOUS 94
14.3.3 OTHERS 94
14.4 TRANSDERMAL 94
14.5 VAGINAL 94
14.6 OTHERS 95
15 CHILE MENOPAUSE DRUGS MARKET, BY END USER 96
15.1 OVERVIEW 97
15.2 HOSPITALS 100
15.3 CLINICS 100
15.4 HOME HEALTHCARE 100
15.5 OTHERS 101
16 CHILE MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL 102
16.1 OVERVIEW 103
16.2 RETAIL PHARMACY 106
16.3 HOSPITAL PHARMACY 106
16.4 ONLINE PHARMACY 106
17 CHILE MENOPAUSE DRUGS MARKET: COMPANY LANDSCAPE 107
17.1 COMPANY SHARE ANALYSIS: CHILE 107
18 SWOT ANALYSIS 108
19 COMPANY PROFILE 109
19.1 BAYER AG 109
19.1.1 COMPANY SNAPSHOT 109
19.1.2 REVENUE ANALYSIS 109
19.1.3 PRODUCT PORTFOLIO 110
19.1.4 RECENT DEVELOPMENTS 110
19.2 PFIZER INC. 111
19.2.1 COMPANY SNAPSHOT 111
19.2.2 REVENUE ANALYSIS 111
19.2.3 PRODUCT PORTFOLIO 112
19.2.4 RECENT DEVELOPMENTS 112
19.3 NOVARTIS AG 113
19.3.1 COMPANY SNAPSHOT 113
19.3.2 REVENUE ANALYSIS 113
19.3.3 PRODUCT PORTFOLIO 114
19.3.4 RECENT DEVELOPMENT 114
19.4 TEVA PHARMACEUTICAL INDUSTRIES LTD 115
19.4.1 COMPANY SNAPSHOT 115
19.4.2 REVENUE ANALYSIS 115
19.4.3 PRODUCT PORTFOLIO 116
19.4.4 RECENT DEVELOPMENTS 116

19.5 KNOP LABORATORIES 117
19.5.1 COMPANY SNAPSHOT 117
19.5.2 PRODUCT PORTFOLIO 117
19.5.3 RECENT DEVELOPMENTS 117
19.6 SAVAL PHARMACEUTICALS 118
19.6.1 COMPANY SNAPSHOT 118
19.6.2 PRODUCT PORTFOLIO 118
19.6.3 RECENT DEVELOPMENT 119
19.7 ITF-LABOMED FARMACEUTICA LTDA. 120
19.7.1 COMPANY SNAPSHOT 120
19.7.2 PRODUCT PORTFOLIO 120
19.7.3 RECENT DEVELOPMENTS 120
19.8 TECNOFARMA S.A. 121
19.8.1 COMPANY SNAPSHOT 121
19.8.2 PRODUCT PORTFOLIO 121
19.8.3 RECENT DEVELOPMENT 121
19.9 MEGALABS CHILE S.A 122
19.9.1 COMPANY SNAPSHOT 122
19.9.2 PRODUCT PORTFOLIO 122
19.9.3 RECENT DEVELOPMENTS 122
19.10 ABBVIE INC. 123
19.10.1 COMPANY SNAPSHOT 123
19.10.2 REVENUE ANALYSIS 123
19.10.3 PRODUCT PORTFOLIO 124
19.10.4 RECENT DEVELOPMENTS 124
19.11 ABBOTT (2021) 125
19.11.1 COMPANY SNAPSHOT 125
19.11.2 REVENUE ANALYSIS 125
19.11.3 PRODUCT PORTFOLIO 126
19.11.4 RECENT DEVELOPMENT 126
19.12 FRESENIUS KABI CHILE 127
19.12.1 COMPANY SNAPSHOT 127
19.12.2 REVENUE ANALYSIS 127
19.12.3 PRODUCT PORTFOLIO 128
19.12.4 RECENT DEVELOPMENT 128
19.13 GLAXO SMITH KLINE PLC(2021) 129
19.13.1 COMPANY SNAPSHOT 129
19.13.2 REVENUE ANALYSIS 129
19.13.3 PRODUCT PORTFOLIO 130

19.14 LABORATORIOS MAVER 131
19.14.1 COMPANY SNAPSHOT 131
19.14.2 PRODUCT PORTFOLIO 131
19.14.3 RECENT DEVELOPMENTS 131
19.15 NOVO NORDISK A/S 132
19.15.1 COMPANY SNAPSHOT 132
19.15.2 REVENUE ANALYSIS 132
19.15.3 PRODUCT PORTFOLIO 133
19.15.4 RECENT DEVELOPMENT 133
19.16 SYNTHON 134
19.16.1 COMPANY SNAPSHOT 134
19.16.2 PRODUCT PORTFOLIO 134
19.16.3 RECENT DEVELOPMENT 134
20 QUESTIONNAIRE 135
21 RELATED REPORTS 138